Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

6.7%

1 terminated/withdrawn out of 15 trials

Success Rate

93.3%

+6.8% vs industry average

Late-Stage Pipeline

60%

9 trials in Phase 3/4

Results Transparency

79%

11 of 14 completed trials have results

Key Signals

11 with results

Enrollment Performance

Analytics

Phase 3

6(40.0%)

Phase 4

3(20.0%)

Phase 1

3(20.0%)

Phase 2

2(13.3%)

N/A

1(6.7%)

15Total

Phase 3(6)

Phase 4(3)

Phase 1(3)

Phase 2(2)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (15)

Showing 15 of 15 trials

NCT01423812Phase 4Completed

DRIVESHAFT: Darunavir/Ritonavir In HIV-infected Virologically-suppressed Experienced Subjects

Role: collaborator

NCT00097981Phase 3Completed

A Study of Thalidomide Plus Dexamethasone (Thal-Dex) Versus DOXIL plusThalidomide Plus Dexamethasone (DOXIL -Thal-Dex) in Patients With Newly Diagnosed Multiple Myeloma

Role: collaborator

NCT00757783Phase 4Completed

Changes in Triglyceride and Other Lipids (Levels of Fats Found in Blood) When Taking Darunavir Compared to Atazanavir in HIV-infected Patients That Have Never Received Treatment

Role: collaborator

NCT00534352Phase 2Completed

A Study to Evaluate the Pharmacokinetic Profile (How the Body Absorbs, Distributes, Metabolizes and Eliminates a Drug) of TMC125 Plus Tenofovir/Emtricitabine Once Daily With or Without Darunavir/r Once Daily in Antiretroviral (ARV) Naive HIV-1 Patients (Patients Have Never Received ARV Treatment).

Role: collaborator

NCT00082095Phase 3Terminated

To Compare Treatment With Doxorubicin or Capecitabine for Metastatic Breast Cancer in Women 60 Years and Older

Role: collaborator

NCT00811954Phase 3Completed

Comparative Study of Three NNRTI-Sparing HAART Regimens

Role: collaborator

NCT01625169Not ApplicableCompleted

Etravirine Pharmacokinetics and HIV Viral Load in Breast Milk and Plasma

Role: collaborator

NCT00183742Phase 1Completed

Trial of Liposomal Doxorubicin (Doxil) and Weekly Docetaxel (Taxotere)

Role: collaborator

NCT00630734Phase 4Completed

Genetic Predictors of Variability in the Drug-drug Interaction Between Darunavir/Ritonavir and Pravastatin

Role: collaborator

NCT00381303Phase 3Completed

GRACE: A Study to Compare the Effectiveness, Safety and Tolerability of PREZISTA (Darunavir)/Ritonavir by Gender and Race When Administered With Other Antiretroviral Medications in Human Immunodeficiency Virus (HIV) Positive Women and Men.

Role: collaborator

NCT01199939Phase 2Completed

A Study of the Once Daily Combination of Etravirine and Darunavir/Ritonavir As Dual Therapy in Early Treatment-Experienced Patients

Role: collaborator

NCT01268839Phase 1Completed

A Phase I, Open-label Trial to Explore the Pharmacokinetics, Safety and Tolerability of TMC278 (Rilpivirine) 25 mg Once Daily Following a 2-week Period Receiving Efavirenz, in Healthy Male and Female Volunteers

Role: collaborator

NCT00460746Phase 3Completed

Enfuvirtide/Current Protease Inhibitor Switch to PREZISTA (Darunavir)/Ritonavir + TMC125 in HIV Patients With Enfuvirtide Side Effects.

Role: collaborator

NCT00344422Phase 3Completed

Vincristine, DOXIL (Doxorubicin HCl Liposome Injection) and Dexamethasone vs. Vincristine, Doxorubicin, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma

Role: collaborator

NCT00871234Phase 1Completed

Effects of Etravirine on Endothelial Function in HIV-uninfected Adults: A Pilot Study

Role: collaborator

All 15 trials loaded